24 Works

Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Abstract Background Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and...

Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.

Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.

Additional file 1 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 1: Table S1. Characteristics and outcome of patients presenting with cefoxitin-susceptible-ESBL-PE infections admitted in the ICU during the study period.

Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.

Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections

Carla Saade, Karen Brengel-Pesce, Alexandre Gaymard, Mary-Anne Trabaud, Gregory Destras, Guy Oriol, Valérie Cheynet, Marion Debombourg, Bouchra Mokdad, Geneviève Billaud, Antoine Oblette, Hervé Créhalet, Jean-Marc Giannoli, Christine Garrigou, Laurence Generenaz, Christelle Compagnon, André Boibieux, Bruno Lina, Florence Morfin, Bruno Pozzetto, Laurence Josset, Sophie Touillet-Assant & Antonin Bal
Omicron variant is circulating in the presence of a globally acquired immunity unlike the ancestral SARS-CoV-2 isolate. Herein, we investigated the normalized viral load dynamics and viral culture status in 44 fully vaccinated healthcare workers (HCWs) infected with the Omicron BA.1 variant. Viral load dynamics of 38 unvaccinated HCWs infected with the 20A variant during the first pandemic wave was also studied. We then explored the impact of Omicron infection on pre-existing immunity assessing anti-RBD...

Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.

Reductive evolution of virulence repertoire to drive the divergence between community- and hospital-associated methicillin-resistant Staphylococcus aureus of the ST1 lineage

Marina Farrel Côrtes, Ana Maria N. Botelho, Paula Terra Bandeira, William Mouton, Cedric Badiou, Michèle Bes, Nicholas C. B. Lima, André Elias R. Soares, Rangel C. Souza, Luiz G. P. Almeida, Patricia Martins-Simoes, Ana T. R. Vasconcelos, Marisa F. Nicolás, Frédéric Laurent, Paul J. Planet & Agnes M. S. Figueiredo
Methicillin-resistant Staphylococcus aureus (MRSA) of the ST1-SCCmecIV lineage has been associated with community-acquired (CA) infections in North America and Australia. In Brazil, multi-drug resistant ST1-SCCmecIV MRSA has emerged in hospital-associated (HA) diseases in Rio de Janeiro. To understand these epidemiological differences, genomic and phylogenetic analyses were performed. In addition, virulence assays were done for representative CA – and HA-MRSA strains. Despite the conservation of the virulence repertoire, some genes were missing in Brazilian ST1-SCCmecIV including...

Reductive evolution of virulence repertoire to drive the divergence between community- and hospital-associated methicillin-resistant Staphylococcus aureus of the ST1 lineage

Marina Farrel Côrtes, Ana Maria N. Botelho, Paula Terra Bandeira, William Mouton, Cedric Badiou, Michèle Bes, Nicholas C. B. Lima, André Elias R. Soares, Rangel C. Souza, Luiz G. P. Almeida, Patricia Martins-Simoes, Ana T. R. Vasconcelos, Marisa F. Nicolás, Frédéric Laurent, Paul J. Planet & Agnes M. S. Figueiredo
Methicillin-resistant Staphylococcus aureus (MRSA) of the ST1-SCCmecIV lineage has been associated with community-acquired (CA) infections in North America and Australia. In Brazil, multi-drug resistant ST1-SCCmecIV MRSA has emerged in hospital-associated (HA) diseases in Rio de Janeiro. To understand these epidemiological differences, genomic and phylogenetic analyses were performed. In addition, virulence assays were done for representative CA – and HA-MRSA strains. Despite the conservation of the virulence repertoire, some genes were missing in Brazilian ST1-SCCmecIV including...

Additional file 1 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 1: Table S1. Characteristics and outcome of patients presenting with cefoxitin-susceptible-ESBL-PE infections admitted in the ICU during the study period.

Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.

Additional file 8 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 8: Table S4. Univariate factors associated with the acquisition of cefoxitin-resistance.

Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Abstract Background Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and...

Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.

Additional file 2 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 2: Table S2. Population PK parameters of cefoxitin.

Additional file 3 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 3: Figure S1. Model prediction versus observed cefoxitin concentrations.

Additional file 7 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 7: Table S3. Univariate factors associated with cefoxitin treatment failure.

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections

Carla Saade, Karen Brengel-Pesce, Alexandre Gaymard, Mary-Anne Trabaud, Gregory Destras, Guy Oriol, Valérie Cheynet, Marion Debombourg, Bouchra Mokdad, Geneviève Billaud, Antoine Oblette, Hervé Créhalet, Jean-Marc Giannoli, Christine Garrigou, Laurence Generenaz, Christelle Compagnon, André Boibieux, Bruno Lina, Florence Morfin, Bruno Pozzetto, Laurence Josset, Sophie Touillet-Assant, Antonin Bal & A. on behalf of Lyon COVID study group
Omicron variant is circulating in the presence of a globally acquired immunity unlike the ancestral SARS-CoV-2 isolate. Herein, we investigated the normalized viral load dynamics and viral culture status in 44 fully vaccinated healthcare workers (HCWs) infected with the Omicron BA.1 variant. Viral load dynamics of 38 unvaccinated HCWs infected with the 20A variant during the first pandemic wave was also studied. We then explored the impact of Omicron infection on pre-existing immunity assessing anti-RBD...

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections

Carla Saade, Karen Brengel-Pesce, Alexandre Gaymard, Mary-Anne Trabaud, Gregory Destras, Guy Oriol, Valérie Cheynet, Marion Debombourg, Bouchra Mokdad, Geneviève Billaud, Antoine Oblette, Hervé Créhalet, Jean-Marc Giannoli, Christine Garrigou, Laurence Generenaz, Christelle Compagnon, André Boibieux, Bruno Lina, Florence Morfin, Bruno Pozzetto, Laurence Josset, Sophie Touillet-Assant & Antonin Bal
Omicron variant is circulating in the presence of a globally acquired immunity unlike the ancestral SARS-CoV-2 isolate. Herein, we investigated the normalized viral load dynamics and viral culture status in 44 fully vaccinated healthcare workers (HCWs) infected with the Omicron BA.1 variant. Viral load dynamics of 38 unvaccinated HCWs infected with the 20A variant during the first pandemic wave was also studied. We then explored the impact of Omicron infection on pre-existing immunity assessing anti-RBD...

Additional file 4 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 4: Figure S2. Visual predictive check obtained with the final model.

Additional file 5 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 5: Figure S3. Probability of target attainment for various cefoxitin doses in patients with CCRIBW = 100 ml/min.

Additional file 6 of Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study

Paul Chabert, Judith Provoost, Sabine Cohen, Céline Dupieux-Chabert, Laurent Bitker, Tristan Ferry, Sylvain Goutelle & Jean-Christophe Richard
Additional file 6: Figure S4. Probability of target attainment for different levels of renal function with a cefoxitin dose of 6g/day.

Data from: 3-D deconvolution of human skin immune architecture with Multiplex Annotated Tissue Imaging System (MANTIS)

Manon Scholaert, Raïssa Houmadi, Jeremy Martin, Nadine Serhan, Marie Tauber, Emilie Braun, Lilian Basso, Eric Merle, Pascal Descargues, Manuelle Viguier, Cecile Lesort, Benoit Chaput, Jean Kanitakis, Denis Jullien, Cristina Livideanu, Laurence Lamant, Emeline Pages & Nicolas Gaudenzio
Routine clinical assays, such as conventional immunohistochemistry, often fail to resolve the regional heterogeneity of complex inflammatory skin conditions. Here we introduce MANTIS (Multiplexed Annotated Tissue Imaging System), a flexible analytic pipeline compatible with routine practice, specifically designed for spatially-resolved immune phenotyping of the skin in experimental or clinical samples. Based on phenotype attribution matrices coupled to alpha-shape algorithms, MANTIS projects a representative digital immune landscape, while enabling automated detection of major inflammatory clusters and...

Registration Year

  • 2023
    1
  • 2022
    21
  • 2021
    2

Resource Types

  • Text
    18
  • Dataset
    3
  • Collection
    2
  • Other
    1

Affiliations

  • Centre Hospitalier Lyon Sud
    24
  • Claude Bernard University Lyon 1
    21
  • Hospices Civils de Lyon
    19
  • Hôpital de la Croix-Rousse
    18
  • University of Lyon System
    18
  • Centre Hospitalier Universitaire d'Angers
    18
  • Inserm
    18
  • Biometry and Evolutionary Biology Laboratory
    18
  • Air Liquide (France)
    18
  • University of Angers
    18